Taysha Gene Therapies (TSHA) Cash from Financing Activities (2020 - 2026)

Taysha Gene Therapies (TSHA) has 7 years of Cash from Financing Activities data on file, last reported at $711000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 1467.31% year-over-year to $711000.0; the trailing twelve-month figure through Mar 2026 stood at $275.4 million (up 259.21% YoY), and the FY2025 full-year result was $274.6 million, up 258.08% from the prior year.
• Cash from Financing Activities fell to $711000.0 in Q1 2026, from $49.6 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $216.3 million in Q2 2025 to a low of -$4.2 million in Q4 2023.
• A 5-year average of $31.8 million and a median of $711000.0 in 2026 frame the typical range for Cash from Financing Activities.
• Peak annual rise in Cash from Financing Activities reached 136637.86% in 2023, while the deepest fall reached 245.79% in 2023.
• Tracing TSHA's Cash from Financing Activities over 5 years: stood at $41.2 million in 2022, then plunged by 110.3% to -$4.2 million in 2023, then soared by 91.6% to -$357000.0 in 2024, then jumped by 13981.23% to $49.6 million in 2025, then tumbled by 98.57% to $711000.0 in 2026.
• Business Quant data shows TSHA's Cash from Financing Activities at $711000.0 in Q1 2026, $49.6 million in Q4 2025, and $8.8 million in Q3 2025.